Cardiol Therapeutics Inc., a clinical-stage biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, an ultra-pure and high concentration cannabidiol oral formulation for the treatment of in hospitalized COVID-19 patients with a prior history of risk factors for CVD; and has completed phase I clinical trials for the treatment of acute myocarditis and other inflammatory heart disease. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability for the treatment chronic heart failure. In addition, it develops proprietary nanotechnology to enable the distribution of water insoluble drugs within the blood circulation, enhance pharmacokinetics, and facilitate drug accumulation in the failing heart. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
IPO Year:
Exchange: NASDAQ
Website: cardiolrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $9.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $7.00 | Buy | Rodman & Renshaw |
| 6/26/2024 | $10.00 | Buy | ROTH MKM |
| 4/22/2024 | $9.00 | Buy | H.C. Wainwright |
| 12/17/2021 | $8.00 | Overweight | Cantor Fitzgerald |
| 12/3/2021 | $8.00 | Buy | Canaccord Genuity |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00
Rodman & Renshaw initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $7.00
ROTH MKM initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Cardiol Therapeutics with a rating of Overweight and set a new price target of $8.00
Canaccord Genuity initiated coverage of Cardiol Therapeutics with a rating of Buy and set a new price target of $8.00
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)
Fastest customizable press release news feed in the world
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). The replay will be available for 90 days following the confere
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.Toronto, Ontario--
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardiac death.There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis.Topline results are expected within the next two weeks.Toronto, Ontario--(Newsfile Corp. - July 22, 20
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161Additional information about the AGM, including details on how to participate and vote, is available on the Company's website at card
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experienceToronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.Dr. Garnett is a distinguished pharmaceutical industry executive with over 30 y
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx™ experienced marked and rapid reductions in pericarditis pain and inflammation, and a substantial reduction in the number of pericarditis recurrences per year.Recurrent pericarditis
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisCash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026Toronto, Ontario--(Newsfile Corp. - April 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) (
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/). About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL)
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failureToronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondr
This live feed shows all institutional transactions in real time.
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G/A - Cardiol Therapeutics Inc. (0001702123) (Subject)
SC 13G - Cardiol Therapeutics Inc. (0001702123) (Subject)
Live Leadership Updates
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: Jennifer Chao, David E
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizationsInitiated patient enrollment in the ARCHER Trial - a Phase II multi-national, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of CardiolRx™ in patients with acute myocarditis, an important cause of acute and sudden heart failure in young adults and a leading cause of sudden cardiac death in people less
Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year:
Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its Board of Directors has appointed Teri Loxam and Chris Waddick to serve as directors, effective immediately. Ms. Teri Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries with diverse roles spanning strategy, investor relations, finance, and communications. Ms. Loxam joined Kira Pharmaceuticals ("Kir
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to senior management team Listed on the NASDAQ stock exchangeEnded 2021 with cash and cash equivalents of $83.9MOakville, Ontario--(Newsfile Corp. - March 24, 2022) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammat
Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed Chair of the Corporate Governance and Compensation Committee. Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy. She is Managing Partner of Cor
Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Ridker, MD, MPH, Bruce McManus, PhD, MD, and Joseph A. Hill, MD, PhD, to its Scientific Advisory Board (SAB). "We are pleased to welcome distinguished thought leaders in cardiovascular medicine to our Scientific Advisory Board," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Their expertise in cardiovascular research
Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Esq. to its Board of Directors, effective immediately.Michael J. Willner has practiced as both an Attorney and a Certified Public Accountant. He graduated from Emory University Law School as a member of the Emory Law Review. Subsequently, he practiced real estate and corporate law with New York City-based Milbank, Tweed, Hadley & McCloy, one of the nat